Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Insurance, Assurance and Insolence.

Texas medical journal (Austin, Tex.)·2023

Same author

Cross-tissue immune cell analysis reveals tissue-specific features in humans.

Science (New York, N.Y.)·2022

Same author

A method to isolate and cryopreserve cerebrospinal fluid mononuclear cells from external ventricular drains to investigate immunological processes in acute brain injuries.

Journal of immunological methods·2021

Same author

Risk factors for <i>Toxoplasma gondii</i> seropositivity in the Old Order Amish.

Epidemiology and infection·2020

Same author

The immunological response to traumatic brain injury.

Journal of neuroimmunology·2019

Same author

Day-case bilateral sagittal split osteotomy.

The British journal of oral & maxillofacial surgery·2018

Same journal

American academy of neurology annual meeting.

International MS journal·2011

Same journal

Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale.

International MS journal·2011

Same journal

The clinical usefulness of routine MRI assessment.

International MS journal·2011

Same journal

Acute Psychosis as the Initial Presentation of MS: A Case Report.

International MS journal·2011

Same journal

Russell Brains Review of MS.

International MS journal·2011

Same journal

Epstein-Barr Virus and MS:Causality or Association?

International MS journal·2011

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Spotlight on alemtuzumab.

J L Jones¹, A J Coles

¹Department of Clinical Neurosciences, Box 165, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK. jls53@medschl.cam.ac.uk

International MS Journal

|November 3, 2009

Summary

This summary is machine-generated.

Alemtuzumab, a monoclonal antibody targeting CD52, significantly reduces relapse and disability in early relapsing-remitting multiple sclerosis (MS). This therapy offers a profound and lasting reduction in lymphocytes, impacting MS pathogenesis and autoimmunity.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

Immunology
Neurology
Pharmacology

Background:

Alemtuzumab is a humanized monoclonal antibody targeting the CD52 protein found on lymphocytes and monocytes.
CD52's function is not fully understood, but alemtuzumab induces rapid, profound, and prolonged lymphopenia.
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.

Purpose of the Study:

To review the experience with alemtuzumab as an experimental treatment for MS since 1991.
To summarize its efficacy in reducing relapse and disability accumulation.
To discuss how this therapy informs basic science regarding MS pathogenesis and lymphopenia-associated autoimmunity.

Main Methods:

Review of clinical experience and data from a Phase II trial.
Comparison of alemtuzumab efficacy against interferon beta in early relapsing-remitting MS patients.
Analysis of alemtuzumab's impact on lymphocyte populations and its implications for MS.

Main Results:

A Phase II trial demonstrated that alemtuzumab reduced the risk of relapse and disability accumulation by over 70% compared to interferon beta.
Alemtuzumab induces a rapid, profound, and prolonged lymphopenia.
The treatment has been utilized experimentally for MS since 1991.

Conclusions:

Alemtuzumab is a highly effective therapy for early relapsing-remitting MS, significantly improving patient outcomes.
The "bench-to-bedside" nature of alemtuzumab continues to provide insights into MS pathogenesis and autoimmunity.
Further research into alemtuzumab's mechanisms may elucidate pathways involved in MS and related autoimmune conditions.